Significance of Elevated Serum Free Light Chain Levels and Abnormal Kappa/Lambda Ratio

Interpretation of Results

• Both kappa and lambda free light chains are significantly elevated above their normal ranges, suggesting either a plasma cell disorder or renal impairment, according to the National Comprehensive Cancer Network 1, 2
• The kappa/lambda ratio is only mildly elevated at 1.75, which is less concerning than a severely abnormal ratio, as stated by the National Comprehensive Cancer Network 3, 4

Clinical Significance

• The serum free light chain assay is an essential component in screening for multiple myeloma and related plasma cell disorders, offering high sensitivity when combined with serum protein electrophoresis and immunofixation, as recommended by the National Comprehensive Cancer Network 1
• A highly abnormal FLC ratio is required for a myeloma-defining event, which would be ≥100 for involved kappa or ≤0.01 for involved lambda, according to the National Comprehensive Cancer Network and Praxis Medical Insights 4, 2
• Early monoclonal gammopathy of undetermined significance (MGUS) may be represented by these findings, as suggested by Haematologica 5

Recommended Next Steps

• A comprehensive evaluation should be completed, including serum protein electrophoresis, immunofixation, 24-hour urine collection for protein electrophoresis and immunofixation, renal function tests, complete blood count, and calcium levels, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
• If initial tests suggest a plasma cell disorder, bone marrow aspiration and biopsy, and skeletal survey or advanced imaging should be performed, as recommended by the National Comprehensive Cancer Network 1, 3

Risk Stratification

• If MGUS is diagnosed, risk stratification should be performed using M-protein level, type of immunoglobulin, and bone marrow plasma cell percentage, as suggested by the National Comprehensive Cancer Network and Haematologica 3, 5, 6
• Low-risk MGUS has approximately 5% risk of progression at 20 years, while non-low-risk MGUS has higher progression risk and requires more frequent monitoring, according to Haematologica 5

Follow-up Recommendations

• If MGUS is diagnosed, follow-up should be done at 6 months, and if stable, every 1-2 years thereafter for low-risk MGUS, and annually for non-low-risk MGUS, as recommended by Haematologica 5
• Follow-up should include serum protein electrophoresis, complete blood count, and quantification of M-protein, as suggested by Haematologica and Nature Reviews Nephrology 5, 6

Management of Increased Kappa/Lambda Free Light Chain Ratio

Interpretation and Management of Elevated FLC Ratio

• A moderately elevated K/L ratio (8.0-100) suggests possible light chain MGUS or smoldering multiple myeloma (SMM), with light chain MGUS defined by abnormal FLC ratio, increased involved light chain, no heavy chain expression on immunofixation, <10% bone marrow plasma cells, and absence of CRAB criteria, according to the International Myeloma Society 7, 8
• Risk stratification for SMM uses three factors (1 point each): bone marrow plasma cells ≥10%, serum M-protein ≥3 g/dL, and FLC ratio <0.125 or >8, as recommended by the International Myeloma Society 7
• Low-risk MGUS (no adverse features) has approximately 5% risk of progression at 20 years, and average progression risk is 1% per year to multiple myeloma or related disorders, according to the European Hematology Association 9
• High-risk SMM (FLC ratio ≥100, or 2-3 risk factors) has a 72-79% risk of progression within 2 years, and consideration of clinical trial enrollment or early treatment intervention is recommended by the National Comprehensive Cancer Network 7
• Active multiple myeloma diagnosis requires immediate treatment if any myeloma-defining events are present, including CRAB criteria, bone marrow plasma cells ≥60%, FLC ratio ≥100 (involved kappa) or ≤0.01 (involved lambda), or more than one focal lesion on MRI, as recommended by the National Comprehensive Cancer Network 8, 10
• At least 100 plasma cells must be analyzed for accurate kappa/lambda ratio determination by immunohistochemistry, according to the College of American Pathologists 11
• Any >25% increase in the difference between involved and uninvolved FLC levels (with absolute increase >10 mg/dL) indicates disease progression, as defined by the International Myeloma Society 10